Follistatin is a glycoprotein, originally isolated from the gonads, that specifically inhibits follicle-stimulating hormone (FSH) biosynthesis and secretion. We have previously detected follistatin mRNA in rat pituitary gonadotropes. To assess the potential physiologic role of follistatin in the rat pituitary, we have investigated the effects of gonadectomy (GDX) and of sex steroid replacement on pituitary follistatin gene expression. Follistatin mRNA levels in individual rat pituitaries were measured by a quantitative reverse transcription-polymerase chain reaction assay. Female and male rats 21 d old underwent surgical GDX and were then killed 21 d after GDX. Follistatin mRNA levels in rat pituitary increased 3.2±1.5-fold (P < 0.01) in GDX female rats and 8.2±2.0-fold (P < 0.005) in GDX male rats, compared with intact female and male controls, respectively. Replacement therapy with 17#-estradiol-3-benzoate (10 ,ug/ 100 g body weight) subcutaneously daily for 7 d in GDX female rats resulted in a slight further increase in follistatin mRNA levels compared to GDX females. In contrast, therapy with testosterone propionate (500 jtg/100 g body weight) subcutaneously daily for 7 d in GDX male rats resulted in a decrease in follistatin mRNA levels, towards but not completely back to baseline levels in intact males. Time-course studies in adult male and female rats showed that the increase in follistatin mRNA levels after GDX is rapid, with significant increases occurring within 24 h after GDX, and parallels or precedes increases in FSH,8 mRNA levels and FSH secretion. The regulation of follistatin mRNA levels in the rat pituitary by GDX and by sex steroids suggests that follistatin may be important as an autocrine or paracrine factor in the regulation of FSH. (J. Clin. Invest. 1993. 91:2523-2531
Introduction
The regulation ofthe biosynthesis and secretion ofthe gonadotropins, follicle-stimulating hormone (FSH)I and luteinizing 1 . Abbreviations used in this paper: CAST, castration; E2, 17f-estradiol-3-benzoate; FSH, follicle-stimulating hormone; GDX, gonadectomy; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; OVX, ovariectomy; RT, reverse transcription; T, testosterone propionate.
hormone (LH), is critical for normal reproductive function ( 1 ) . The synthesis and release ofthese two pituitary hormones are controlled by the complex interactions of multiple factors, including hypothalamic gonadotropin-releasing hormone (GnRH) and gonadal steroids (2) . In addition, a number of peptides have recently been identified that specifically influence FSH biosynthesis and secretion and thus contribute to differential regulation of FSH and LH during the estrous or menstrual cycle. These include inhibins, activins, and follistatin (3) (4) (5) .
Inhibins and activins are structurally related proteins belonging to a family of growth and differentiation factors that includes TGFB (6) . These peptides were originally isolated from ovarian follicular fluid, but the inhibin/activin subunits and their messenger ribonucleic acids (mRNAs) have subsequently been detected not only in the ovaries and testes, but also in many extragonadal tissues, including the pituitary (7). Inhibin decreases, whereas activin increases FSHt mRNA levels, cell content, and secretion (8, 9) . Treatment ofcultured rat anterior pituitary cells with a monoclonal antibody specific for activin B suppresses basal FSH secretion (1O), which suggests that activin B may be produced locally in the pituitary and may serve as an autocrine or paracrine signal in the regulation of FSH biosynthesis and secretion.
Follistatin, like inhibins and activins, was originally isolated and purified from ovarian follicular fluid (11) (12) (13) . Although its effects are similar to those of inhibin, it is structurally distinct. Follistatin is a monomeric glycoprotein that suppresses the basal cell content and release ofFSH in rat pituitary cells in vitro (14, 15) as well as inhibiting the synthesis and secretion of FSH induced by activin and GnRH (8, 16) . No effects of follistatin on LH synthesis or secretion have been shown. Similar effects offollistatin have been demonstrated on ovariectomized rats in vivo ( 17 ) . Follistatin mRNA has been detected in a wide variety ofextragonadal tissues, including the kidney, cerebral cortex, and decidual tissue (18) (19) (20) . In addition, we and others have detected follistatin mRNA in the rat pituitary (20) (21) (22) (23) . The synthesis of follistatin by the pituitary suggests that follistatin, like activin B, may have an autocrine or paracrine role in the regulation of FSH biosynthesis and secretion. It has been shown that follistatin is able to bind activin, and it has been postulated that the effects of follistatin on FSH synthesis and secretion may be mediated indirectly by binding to and thereby modulating the effects ofactivin (23) (24) (25) .
To begin to assess the potential physiological importance of follistatin as an autocrine or paracrine factor in the regulation of FSH in the rat pituitary, we studied the effects of endocrine manipulations that are known to Poly A( +) RNA was prepared from 500 ,ug oftotal pituitary RNA from intact and GDX female and male rats, using oligo (dT) columns (Pharmacia, Inc., Piscataway, NJ). These RNA samples, as well as 20 gg of total RNA from mature rat ovaries, rat kidney, and rat liver were submitted to RNase protection analysis using a specific rat follistatin antisense RNA probe, as described previously (21) . The detection of a protected fragment of follistatin mRNA that is 168 nucleotides in length was predicted. A DNA sequence ladder was used as molecular size markers. Autoradiography was performed on X-ray film (Eastman Kodak Co., Rochester, NY) with an intensifying screen at -70°C for 18 h.
Quantitative RT-PCR assay Oligonucleotide primers were designed based on the sequence of rat follistatin such that the expected product would be 337 basepairs in length, as described previously (21 ) . A competitive template was generated by subcloning a 42-basepair random sequence oligonucleotide into an XbaI site within the 337-basepair fragment. This competitive template could thus be amplified by PCR by the same primers to generate a 379-basepair product. The developed protocol is modified from that described by Gilliland et al. (27) (28) . Each blot was hybridized successively with FSHfl and LH,3 cDNA probes, using conditions previously described (29, 30) . Blots were washed and subjected to autoradiography, and band densities were determined by laser densitometry (Molecular Dynamics).
RIA ofFSH and LH
Serum levels of rat FSH and LH were determined by RIAs using reagents from the National Institute ofArthritis, Metabolism, and Digestive Diseases (Bethesda, MD), as described previously (30, 31 ) , except that RP-2 standards were used for the FSH RIA, and RP-3 standards were used for the LH RIA. The FSH assay had a sensitivity of 190 pg/ ml, an interassay variability of7.9%, and an intraassay variability of 10.7%. The LH assay had a sensitivity of 54 pg/ml, an interassay variability of 12.0%, and an intraassay variability of 10.9%.
Standardization ofdata
The total amounts of RNA in each sample were internally standardized by determining the level of 18S RNA for each sample by laserdensitometry of negative image photographs of Northern blots and correcting the follistatin, FSHf3, and LH# mRNA levels accordingly (32) .
Statistical analysis
A t test for independent samples was used to assess the statistical significance of changes in follistatin, FSHf3, and LHB mRNA levels and changes in serum FSH and LH levels.
Results
RNase protection assay Male and female rats underwent GDX at the age of 21 d, and animals were killed and pituitaries were isolated at 21 d post-GDX. Intact adult male and female rats were used as controls.
Poly A( +) RNA was prepared from 500 ,ug of total pituitary RNA from each group of rats. These RNA samples, as well as 20 ,ug of total RNA from rat ovaries, kidney, and liver, were hybridized with a specific rat follistatin riboprobe and subjected to ribonuclease digestion. Protected fragments were analyzed by denaturing polyacrylamide gel electrophoresis, followed by autoradiography. A protected fragment of the expected size (168 nucleotides) was seen in all pituitary RNA samples ( Fig. 1 ), corresponding to that detected previously (21 ) . Follistatin mRNA levels were increased by GDX in both female and male rat pituitaries compared to levels in intact female and male rat pituitaries, respectively. A protected fragment of the same size was seen in rat ovary and kidney RNA, used as positive controls. No protected fragments were detected in rat liver RNA, used as a negative control.
We wanted to confirm these results and to study this phenomenon further by examining the effects of sex steroid replacement ofGDX rats on pituitary follistatin gene expression. However, RNase protection analysis was of limited utility as a method for these studies because of the prohibitively large amounts ofpituitary RNA required to detect follistatin mRNA reliably. Therefore, we developed a quantitative RT-PCR assay.
Quantitative RT-PCR assay In all subsequent experiments to assess follistatin mRNA levels in the rat pituitary, the quantitative RT-PCR assay was used. Total RNA from individual rat pituitaries was prepared, followed by RT using an oligo(dT)121,8 primer to generate cDNAs for use as templates for PCR amplification. Amplification by PCR was performed using two specific rat follistatin primers, producing an easily detected amplification product of the expected size (21) . In order to quantitate the amplified product and to control for the efficiency of PCR amplification, a competitive template was added to all PCR reactions. This template was coamplified by the same primers used to amplify follistatin, but was modified by the insertion ofa random oligonucleotide to generate a product of a slightly larger size. For each target cDNA sample generated by RT from a rat pituitary RNA sample, a series of PCR reactions was performed, such that follistatin cDNA was coamplified with a dilution series of competitor DNA of known concentration (for example, see Fig. 2 ). Polyacrylamide gel electrophoresis ofthe PCR amplification products followed by autoradiography and densitometric analysis allowed the amplified products of the follistatin cDNA and the competitive template to be distinguished and quantitated. The ratio of the products was then used to determine the concentration offollistatin cDNA generated from the pituitary RNA sample. The relative amounts of follistatin mRNA in individual rat pituitary samples could thus be compared.
As a negative control, corresponding RNA samples from each rat pituitary were treated identically except for the omission of reverse transcriptase. These (Fig. 3 A) . Similarly, in female rats, pituitary follistatin mRNA levels were also increased 21 . Each bar represents the mean±SEM for three to five rats. *P < 0.01, significantly different from intact rats; **P < 0.01, significantly different from GDX rats.
females, although to a lesser extent, increasing by 3.2±1.5-fold (P < 0.01 ) (Fig. 3 B) . These results are in agreement with the results of the RNase protection assay. Analysis of follistatin mRNA levels in the pituitaries of CAST male rats treated with T for 7 d revealed a decrease of 2.9±1.0-fold (P < 0.01 ) when compared to CAST males; however, levels were still 3.2±0.8-fold (P < 0.005) above those in intact male rats. In contrast, pituitary follistatin mRNA levels did not decrease in OVX female rats in response to 7 d oftreatment with E2; in fact, levels tended to increase somewhat, although the increase did not reach statistical significance.
As shown in Table I , in male rats, pituitary LHf3 mRNA levels and serum LH levels increased appropriately in response to CAST, and decreased appropriately in response to T therapy (29) . Pituitary FSHI3 mRNA levels increased after GDX, but did not change significantly in response to T replacement, in (Fig. 4) . Levels continued to increase progressively with time, and were increased 20.6±5.8-fold (P < 0.0005) over levels in intact adult male rats by 21 d post-CAST. Replacement with T resulted in a prompt decrease in pituitary follistatin mRNA Pituitary LH/3 mRNA and serum LH levels increased promptly after CAST, and decreased acutely in response to T replacement, returning to baseline levels seen in intact adult male rats. Pituitary FSHJ and serum FSH levels also increased after CAST; however, the increase was more gradual and less marked than the changes seen in LH. Levels did decrease somewhat with T replacement, but again more gradually than LH, and levels did not return to baseline values (data not shown).
Females. Similar studies were performed in females. Adult female rats underwent surgical OVX and were divided into two groups. In the first group, rats were sacrificed and pituitaries were isolated 1, 3, 7, 14, or 21 d post-OVX. In the second group, adult female rats 21 d post-OVX were given daily subcutaneous injections with E2 and were killed 8 h or 1, 2, or 7 d after injections were initiated. Four to seven rats were analyzed for each time point. Follistatin mRNA levels in individual rat pituitaries were measured by the quantitative RT-PCR assay as described. Levels of pituitary follistatin mRNA were increased significantly (P < 0.0005) by 24 h post-OVX, the earliest time point examined (Fig. 5) . Interestingly, levels then decreased somewhat at 
Discussion
This study examines the regulation of follistatin gene expression in the rat pituitary. The presence of follistatin in the rat pituitary has been documented previously (20) (21) (22) (23) , but the physiologic importance of follistatin as a potential autocrine or paracrine factor in the regulation of FSH biosynthesis and secretion is not known. The regulation of follistatin gene expression in the rat pituitary by GDX and by gonadal steroid replacement, which also modulate FSH biosynthesis and secretion, suggests that the local production of follistatin in the rat pitu- The regulation of the biosynthesis and secretion of FSH and LH has been well characterized in female and male rats after GDX and after replacement with estrogen and testosterone (29, 30) , and therefore this provides a good animal model in which to study the regulation of pituitary follistatin gene expression. The doses of E2 and T administered in this study were chosen because they are supraphysiologic and the responses of FSH and LH at both the pre-and posttranslational levels have been well characterized previously (29, 30, 33, 34) . However, in view of the supraphysiological doses of E2 and T used in these replacement experiments, the data should be interpreted with care regarding their physiological implications.
RNase protection analysis was initially used as an assay to quantitate the levels of follistatin mRNA present in the rat pituitary under the different experimental conditions. This method gave a reproducible signal of the expected size and showed an increase in the signal after GDX in both male and female rats, reflecting an increase in follistatin mRNA levels. However, RNase protection analysis required the use of large amounts of total pituitary RNA to detect and quantitate the follistatin mRNA signal reliably, and was therefore impractical as a method to study the regulation of pituitary follistatin gene expression in more detail. We therefore developed a quantitative RT-PCR assay.
In the quantitative RT-PCR assay, mRNA was first converted to cDNA, and follistatin cDNA was then amplified using specific oligonucleotide primers. This assay is extremely sensitive due to the exponential nature of the amplification (35) ; therefore, much smaller quantities of RNA could be used, allowing the detection of follistatin mRNA in RNA samples from individual rat pituitaries. The inclusion ofa competitive template DNA allowed accurate quantitation of follistatin cDNA, and hence of follistatin mRNA (27) . Amplification of both follistatin cDNA and its competitive template used the same primers and therefore all variables which affect the efficiency ofamplification would affect both products equally. Accordingly, the ratio of follistatin cDNA product to competitor product should remain constant throughout the amplification process, and the ratio of these amplified products should precisely reflect the initial concentration of follistatin cDNA versus the concentration of the added competitive template.
Initial studies comparing the levels of follistatin mRNA in the pituitaries of intact and GDX rats by the quantitative RT-PCR assay showed an increase in pituitary follistatin mRNA levels in both female and male rats after GDX. These results are in agreement with the results ofthe RNase protection assay, thus confirming the increase in pituitary follistatin gene expression following GDX and validating the quantitative RT-PCR assay as a means for quantitating follistatin mRNA levels in individual rat pituitary samples. The increase in follistatin gene expression in both female and male rats after GDX, a procedure which also causes an increase in FSH biosynthesis and secretion, suggests that the local production of follistatin in the rat pituitary may have important physiologic consequences.
The mechanism(s) of action of follistatin in the pituitary remains speculative at this point. It is known that follistatin is an activin-binding protein (23) (24) (25) , and it has been shown in the pituitary and other tissues that follistatin can interfere with the actions of activin (8, (36) (37) (38) . One possible mechanism of action, therefore, is that follistatin binds to activin in the pituitary, derived either from local production or from the circulation, and thereby prevents the binding ofactivin to its receptor, resulting in the inhibition of FSH synthesis and secretion (Fig.  6 A) . However, based on this model, we would predict that follistatin gene expression in the pituitary should decrease in response to GDX, resulting in a decrease in activin binding by follistatin, allowing more free activin to act on gonadotropes to stimulate FSH biosynthesis, and contributing to the increase in FSH levels that occurs after GDX. To reconcile the increase in follistatin mRNA levels which occurs after GDX with this model, one could speculate that the increase in follistatin occurs only in response to the rising FSH levels, and serves to inhibit an even greater or excessive rise in FSH biosynthesis after GDX. However, follistatin mRNA levels increased promptly after GDX, and the rise in follistatin paralleled or even preceded the increase in FSH,3 mRNA levels, making this possibility less likely.
An alternative mechanism of action of follistatin may be invoked to account for the increase of follistatin gene expression that occurs after GDX (Fig. 6 B) In OVX female rats, treatment with E2 did not reverse the increase in follistatin mRNA levels seen after OVX. In fact, follistatin mRNA levels increased after E2 treatment compared to vehicle-treated control animals. These results suggest that E2 does not inhibit follistatin gene expression, but may have a weak stimulatory effect. The increase in follistatin mRNA levels seen after OVX is therefore not due to the reduction in circulating estrogen. One must postulate that there is some other ovarian factor(s) that inhibits pituitary follistatin gene expression, directly or indirectly, such that OVX removes this inhibitory effect and allows follistatin mRNA levels to increase. One possible candidate for this inhibitory factor is inhibin, which is known to be produced in the ovary and to be an important factor involved in the inhibition of FSH synthesis and secretion (3) (4) (5) . The biphasic response of levels of pituitary follistatin mRNA after OVX (a rapid rise within 24 h after OVX, followed by a decrease at 3 and 7 d post-OVX, before increasing further at 14 and 21 d post-OVX) supports our suggestion that multiple factors are involved in the regulation of pituitary follistatin gene expression. At this point, we can only speculate on possible mechanisms to account for this pattern. For example, it is possible that the removal ofan inhibitory gonadal factor(s) such as inhibin causes the rapid increase in follistatin mRNA seen at 24 h post-OVX. Subsequent changes in levels of pituitary follistatin mRNA may then be due to the interactions of several other direct and indirect effects of OVX, such as the removal of other ovarian factors, changes in hypothalamic function such as GnRH pulse amplitude and frequency, as well as changes in other putative pituitary paracrine factors. Further studies both in vivo and in vitro are necessary to identify the mediators of the changes in pituitary follistatin mRNA levels after OVX and after E2 replacement.
In contrast, in GDX male rats, treatment with T caused a decrease in pituitary follistatin mRNA levels. This decrease was rapid, and follistatin mRNA levels were significantly reduced by 24 h after T treatment was initiated, which was the earliest time point examined. Follistatin levels returned towards but not entirely back to baseline levels seen in intact male rats after 7 d of treatment with T. The increase in follistatin gene expression in male rats after CAST may therefore be due, at least in part, to the removal of inhibitory effects of testosterone produced and secreted by the testis. However, there may be another inhibitory factor(s) produced by the testis that also contributes to the increase in pituitary follistatin after CAST. This would account for the failure of follistatin mRNA levels to return to baseline after treatment with T. One can again speculate that this second inhibitory factor present in the testis is inhibin. Further studies are necessary to test this hypothesis. The presence of at least two putative follistatin-inhibitory factors in the testis versus a possible single putative inhibitory factor in the ovary may explain why the increase in follistatin mRNA levels following GDX was greater in male rats versus female rats.
The differential regulation of follistatin mRNA levels by estrogen and androgen is particularly interesting because it implicates follistatin as a possible mediator of the sexually dimorphic regulation of FSH which occurs in the rat. FSHB mRNA levels are negatively regulated by E2 in vivo (30, 33 ). In contrast, FSHB mRNA levels are less sensitive to negative regulation by T in vivo (30, 33) . Furthermore, differential effects of estrogen and androgen occur directly at the level of the pitu-B itary. In primary rat pituitary cultures, testosterone stimulates FSHf mRNA levels, whereas estrogen has no effect (46) . In view of the differential effects of estrogen and testosterone on pituitary follistatin as well as on FSHJ mRNA levels, it is possible that follistatin is involved in mediating the effects of estrogen and androgen on FSH.
In conclusion, GDX results in an increase in follistatin mRNA levels in the pituitaries of both female and male rats that parallels or precedes the increase in FSH biosynthesis and secretion. E2 replacement in OVX female rats does not reverse this increase, but, in fact, stimulates a further increase in pituitary follistatin mRNA levels. In contrast, T replacement in CAST male rats causes a decrease in pituitary follistatin mRNA levels. The regulation of follistatin gene expression in the rat pituitary by gonadectomy and by sex steroid replacement suggests the local production of follistatin in the rat pituitary may have important physiological consequences. In order to understand fully the regulation of the hypothalamic-pituitary-gonadal axis, the roles of inhibin, activin, and follistatin as endocrine and/or paracrine factors need to be further elucidated.
